Genmab ( (GMAB) ) has provided an update.
On February 25, 2025, Genmab A/S announced a capital increase of 10,058 shares due to the exercise of employee warrants, generating approximately DKK 11.4 million. The new shares, which account for about 0.02% of the company’s share capital, will be listed on Nasdaq Copenhagen, enhancing Genmab’s financial position and operational flexibility. This move reflects the company’s ongoing efforts to support its growth and innovation in the biotechnology sector.
More about Genmab
Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: 7.14%
Average Trading Volume: 1,340,062
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.24B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.